Biotech, Provenge, Prostate Cancer

Dendreon Reports $106M in Cash at End of September

Luke Timmerman 11/7/08

Dendreon said today in its quarterly report that it finished the month of September with $106 million in cash and investments in the bank. The Seattle biotech company (NASDAQ: DNDN) said its net loss in the quarter was $26.8 million. It expects to get final clinical results from a trial of its leading prostate cancer drug candidate, Provenge, by the middle of 2009.

Luke Timmerman is the National Biotechnology Editor for Xconomy. You can email him at ltimmerman@xconomy.com or call 206-624-2374.